about
sameAs
Prevalence, clinical profile, and prognosis of NPM mutations in AML with normal karyotype.Wilms tumor 1 gene mutations are associated with a higher risk of recurrence in young adults with acute myeloid leukemia: a study from the Acute Leukemia French Association.TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs).Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine.Clinical significance of HOX11L2 expression linked to t(5;14)(q35;q32), of HOX11 expression, and of SIL-TAL fusion in childhood T-cell malignancies: results of EORTC studies 58881 and 58951TPA stimulation culture for improved detection of t(11;14)(q13;q32) in mantle cell lymphomaImatinib plus peginterferon alfa-2a in chronic myeloid leukemia.Chromosomal minimal critical regions in therapy-related leukemia appear different from those of de novo leukemia by high-resolution aCGH.Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study.Fractionated gemtuzumab ozogamicin and standard dose cytarabine produced prolonged second remissions in patients over the age of 55 years with acute myeloid leukemia in late first relapse.Haematological spectrum and genotype-phenotype correlations in nine unrelated families with RUNX1 mutations from the French network on inherited platelet disorders.Clinical impact of gene mutations and lesions detected by SNP-array karyotyping in acute myeloid leukemia patients in the context of gemtuzumab ozogamicin treatment: results of the ALFA-0701 trial.ASXL2 is essential for haematopoiesis and acts as a haploinsufficient tumour suppressor in leukemia.Comprehensive mutational profiling of core binding factor acute myeloid leukemia.Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study.Frequent ASXL2 mutations in acute myeloid leukemia patients with t(8;21)/RUNX1-RUNX1T1 chromosomal translocations.Mutations in the ABL kinase domain pre-exist the onset of imatinib treatment.MRD assessed by WT1 and NPM1 transcript levels identifies distinct outcomes in AML patients and is influenced by gemtuzumab ozogamicin.MYD88 L265P mutation contributes to the diagnosis of Bing Neel syndrome.C/EBPα regulated microRNA-34a targets E2F3 during granulopoiesis and is down-regulated in AML with CEBPA mutationsEffect of priming with granulocyte-macrophage colony-stimulating factor in younger adults with newly diagnosed acute myeloid leukemia: a trial by the Acute Leukemia French Association (ALFA) Group.Superior long-term outcome with idarubicin compared with high-dose daunorubicin in patients with acute myeloid leukemia age 50 years and older.A certified plasmid reference material for the standardisation of BCR-ABL1 mRNA quantification by real-time quantitative PCRSerum 2-hydroxyglutarate production in IDH1- and IDH2-mutated de novo acute myeloid leukemia: a study by the Acute Leukemia French Association group.Fast multiclonal clusterization of V(D)J recombinations from high-throughput sequencing.The role of intensive chemotherapy in myelodysplastic syndromes.Dasatinib in high-risk core binding factor acute myeloid leukemia in first complete remission: a French Acute Myeloid Leukemia Intergroup trial.GILZ inhibits the mTORC2/AKT pathway in BCR-ABL(+) cells.Germ-line GATA2 p.THR354MET mutation in familial myelodysplastic syndrome with acquired monosomy 7 and ASXL1 mutation demonstrating rapid onset and poor survival.Diagnosis of intrachromosomal amplification of chromosome 21 (iAMP21) by molecular cytogenetics in pediatric acute lymphoblastic leukemiaNext-generation sequencing of FLT3 internal tandem duplications for minimal residual disease monitoring in acute myeloid leukemia.IDH1/2 but not DNMT3A mutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the Acute Leukemia French Association.Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents.Prospective long-term minimal residual disease monitoring using RQ-PCR in RUNX1-RUNX1T1-positive acute myeloid leukemia: results of the French CBF-2006 trial.Acute myeloid leukemia with translocation t(3;5): new molecular insights.Epidemiologic study on survival of chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia patients with BCR-ABL T315I mutation.Effect of lenalidomide treatment on clonal architecture of myelodysplastic syndromes without 5q deletionCooperating gene mutations in acute myeloid leukemia: a review of the literature.NUP214-ABL1 fusion defines a rare subtype of B-cell precursor acute lymphoblastic leukemia that could benefit from tyrosine kinase inhibitorsCD3-CD4+ lymphoid variant of hypereosinophilic syndrome: nodal and extranodal histopathological and immunophenotypic features of a peripheral indolent clonal T-cell lymphoproliferative disorder.
P50
Q27824842-3EA03357-ED87-461B-8467-CCD2F4D0A8D4Q27851473-0968E52F-CE44-441C-A92A-CD5713398937Q27851480-B6CD9C4B-32FD-4BEA-A237-C1AB054F7019Q27853006-28690FEB-2D90-41D2-BE59-14302722B136Q28204365-79A61461-D35B-4AC1-897D-8DE48C9F0025Q28207718-965C6D81-B404-45A1-8F99-C90C137BD5FDQ33393383-A8253EB0-C8A9-49E9-A262-74DA5F9FC0F7Q33394269-BE4C6D39-E0AB-496A-8702-04440F15AEBFQ33400617-44EDF045-C5F5-4C77-A00D-562D2BC88DCCQ33412354-4F1DD54F-9B40-484F-A005-A9EA462A50BFQ33431735-E6E3CF97-EDB2-49FF-BCD2-DFE0505564B9Q33572303-BB77DF76-7C7E-4CC0-AE27-813043360250Q33753763-D2EC2E1A-94A4-4C50-9497-7815DA9DC453Q33758306-1F5056B4-F7FB-40B2-86A8-11407E6B7808Q34046624-FAC92A5B-3A5A-4A90-8E04-96EF8B62B0FAQ34106837-18467AB2-DCCA-4ED4-94FC-C496B9FA96A6Q34202519-C291A1CD-8B46-488F-BA98-1C2681F00B30Q34227693-7BE5297C-2221-4CC5-8919-60EBD47D986AQ34435295-002B9D1F-A109-47A9-A454-108E779C809FQ34541735-666EA2DF-9A12-4BC2-9AA1-B808C1E9772EQ34574352-9F1E4702-B8A3-4816-BB21-616D5AC2F7B1Q34646570-BFAC8316-8954-4B92-8402-4CEBAAD9BA82Q35059443-E0FA5664-7204-4CB5-B091-F3FED80C4CE4Q35068764-E394931A-6FC0-405B-98EE-E10D814A602AQ35178180-3249897C-53D0-4618-BF47-78407D05BBC1Q35664739-BCCA6FB8-8A05-4650-A710-5A989E554C69Q35669870-DD9CB56F-EB7A-4125-ACB7-9D3585903369Q35853026-F33AA9A7-04DE-4D09-B570-2369D4159B19Q36006394-A2640503-5B4A-4AB8-AECB-C70C71DD35DCQ36188346-752AB416-B7CE-43B7-A701-2734FD39294CQ36356082-1E90A676-BD7B-4E39-87BC-B71133787D61Q36561772-6107D225-43E8-4DAE-A3D8-2A75087E9E2CQ36627526-0AE3BE41-87B2-46E4-8EE5-043EEA34F7F5Q36750458-5DBF26C7-2D11-4481-8C0E-470AAB4743C7Q36862568-547B3A7B-0073-4D1E-B589-29A117739128Q37028628-996B9363-7C82-4393-9F32-101E6F1CE2A2Q37075929-925C1137-2A1A-444B-BC1A-13E63077F3B0Q37089717-7E566148-B339-486A-A03E-813EEE3BA6E0Q37216300-923C69ED-1CD1-4CCD-ADF0-5A6D097477CEQ37216376-2E4A5037-2821-4922-85FE-19202694E997
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Claude Preudhomme
@ast
Claude Preudhomme
@en
Claude Preudhomme
@es
Claude Preudhomme
@nl
Claude Preudhomme
@sl
type
label
Claude Preudhomme
@ast
Claude Preudhomme
@en
Claude Preudhomme
@es
Claude Preudhomme
@nl
Claude Preudhomme
@sl
prefLabel
Claude Preudhomme
@ast
Claude Preudhomme
@en
Claude Preudhomme
@es
Claude Preudhomme
@nl
Claude Preudhomme
@sl
P106
P21
P31
P496
0000-0002-1267-9546